Seasonal Allergic ConjunctivitisPhase 3NCT05591755

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

A Phase 3 study testing Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035% and Brimonidine tartrate ophthalmic solution 0.025% in people with Seasonal Allergic Conjunctivitis, run by Bausch & Lomb Incorporated at 6 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Seasonal Allergic Conjunctivitis
What is being tested?: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035% and Brimonidine tartrate ophthalmic solution 0.025%
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 229 participants
Where: 6 sitesUnited States
Study dates: 18 Nov 2022to 9 Aug 2023
Phase: Phase 3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Subjects must:
be at least 18 years of age of either sex and any race;
provide written informed consent and sign the Health Information Portability and Accountability Act (HIPAA) form;
be willing and able to follow all instructions and attend all study visits;
provide proof of COVID-19 vaccination
be able and willing to discontinue wearing contact lenses for at least 72 hours prior to Visit 2 and for the duration of the visit;

Show all 11Show fewer

have seasonal allergic conjunctivitis to ragweed or timothy grass documented by a self-reported history of ocular allergic symptoms for the last 2 consecutive years during the ragweed or timothy grass seasons and a positive skin test reaction to ragweed or timothy grass pollen as confirmed by the allergic skin test given at or within 24 months of the subject's Visit 1;
(If female and of childbearing potential) agree to have urine pregnancy testing performed at visit 2, (must be negative); must not be lactating; and must agree to use at least 1 medically acceptable form of birth control throughout the study duration, for at least 14 days prior to and 1 month after receiving investigational drug. Acceptable forms of birth control are true abstinence (when this is in line with the preferred and usual lifestyle of the subject), spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of male partner at least 3 months prior to receiving investigational drug (Visit 2). Note: Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
(If male and with female partner of childbearing potential) must use at least 1 medically acceptable form of birth control· Note: Acceptable forms of birth control are true abstinence (when this is in line with the preferred and usual lifestyle of the subject) or vasectomy at least 3 months prior to receiving investigational drug (Visit 2). Without a vasectomy, must use condoms with spermicidal foam/gel/film/cream/suppository throughout the study duration, for at least 14 days prior to and 1 month after investigational drug (Visit 2).
have a calculated visual acuity (VA) of 0.7 logMAR or better in each eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Visit 1;
have a positive Allergen BioCube challenge response to pollen exposure at the 90 minute time point of ABC exposure at Visit 2, defined as bilateral score of >2 in ocular itching and ocular redness.

Who cannot join

Subjects may not:
have known contraindications or sensitivities to the use of any of the investigational product medication or components;
have a history of mild persistent, moderate or severe asthma within the preceding 5 years according to the National Heart, Blood, and Lung Institute classification (with the exception of exercise induced asthma).
Note: Subjects with fall induced asthma that is either mild persistent (defined as >1 per week, but <1 per day), moderate persistent, or severe persistent will be excluded.
have an upper respiratory tract or sinus infection within the previous 2 weeks of Visit 1;
have a history of anaphylaxis or poor tolerability of previously administered allergen;

Show all 10Show fewer

have a compromised lung function at Visit 1 (defined as a peak expiratory flow rate [PEFR] that is below 80% of the predicted average PEFR, as calculated by gender, age, and measured height from the Mini-Wright instruction's table: Normal Adult Predicted Average Peak Expiratory Flow).
have an abnormal blood pressure (defined as ≤ 90 or ≥ 160 (systolic) measured in mmHg or ≤ 60 or ≥ 100 (diastolic) measured in mmHg) at Visit 1;
have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters (including but not limited to narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium, or a diagnosis of dry eye);
have had ocular surgical intervention within three months prior to Visit 1, or during the trial or a history of refractive surgery six months prior to Visit 1, or have systemic surgery planned during the clinical trial or within 30 days after;

Trial locations and contacts

6 sites in 1 country.

City, postcode or hospital

6 sites in 1 country

United States6 sites

101 Andover Eye Associates
Andover, Massachusetts, 01810
108 Emerson Clinical Research Institute Inc.
Falls Church, Virginia, 22046
105 - Advancing Vision Research
Goodlettsville, Tennessee, 37072
104 Butchertown Clinical Trials
Louisville, Kentucky, 40206
102 Total Eye Care, PA
Memphis, Tennessee, 38119
107 Virginia Eye Institute
Richmond, Virginia, 23230

Other trials in United States

About this study

Official title: Evaluation of the Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle in an Allergen BioCube® in Subjects With Seasonal Allergic Conjunctivitis

To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.

Conditions: Seasonal Allergic Conjunctivitis
Being tested: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionDrug
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Ketotifen fumarate ophthalmic solution 0.035%Drug
Ketotifen fumarate ophthalmic solution 0.035%
Brimonidine tartrate ophthalmic solution 0.025%Drug
Brimonidine tartrate ophthalmic solution 0.025%
Experimental: Vehicle ophthalmic solutionDrug
Experimental: Vehicle ophthalmic solution

Study groups in NCT05591755
Study group	Role	What they receive
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution	Experimental	Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution Receives: Drug: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Ketotifen fumarate ophthalmic solution 0.035%	Experimental	Ketotifen fumarate ophthalmic solution 0.035% Receives: Drug: Ketotifen fumarate ophthalmic solution 0.035%
Brimonidine tartrate ophthalmic solution 0.025%	Experimental	Brimonidine tartrate ophthalmic solution 0.025% Receives: Drug: Brimonidine tartrate ophthalmic solution 0.025%
Vehicle ophthalmic solution	Experimental	Vehicle ophthalmic solution Receives: Drug: Experimental: Vehicle ophthalmic solution

What is being measured

The primary outcome is the main question the study is designed to answer.

Ocular Itching Symptom Score
Ocular itching score evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 is the worse outcome.
Measured: Assessed up to 480 minutes post-instillation of assigned IP
Ocular Redness Measured by Ocular Itching Scale
Ocular redness evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.
Measured: Assessed up to 480 minutes post-instillation of assigned IP

Secondary outcomes (3)

Tearing Measured by Watery Eyes Scale
Tearing evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, NOT allowing half unit increments), with 4 being the worse outcome.
Measured: up to 480 minutes post-instillation of assigned IP
Lid Swelling Measured by Eyelid Swelling Scale
Lid swelling evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-3 scale, NOT allowing half unit increments), with 3 being the worst outcome
Measured: up to 480 minutes post-instillation of assigned IP
Chemosis Evaluated
Chemosis evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.
Measured: up to 480 minutes post-instillation of assigned IP

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

18 Nov 20229 Aug 2023

First posted24 Oct 2022
Study start18 Nov 2022
Primary completion9 Aug 2023
Study completion9 Aug 2023

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Seasonal Allergic ConjunctivitisStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 229 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05591755
Sponsor's protocol ID: 910
Status last verified: Jun 2025
First submitted: 6 Oct 2022
Last updated: 1 Jul 2025
Results posted: Yes, on ClinicalTrials.gov
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingObservational study
Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure
Allergic Rhinoconjunctivitis
Active, not recruitingObservational study
Tyrosine Allergoid Paediatric and Adult Study
Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis
RecruitingPhase 2
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
Allergic Conjunctivitis

All Seasonal Allergic Conjunctivitis trials

Study at a glance

From the registry record, last updated by the sponsor on 1 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Evaluation of the Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle in an Allergen BioCube® in Subjects With Seasonal Allergic Conjunctivitis
ClinicalTrials.gov ID: NCT05591755
Acronym / sponsor ID: 910
Conditions: Seasonal Allergic Conjunctivitis
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 229 participants (actual)
Lead sponsor: Bausch & Lomb IncorporatedIndustry (pharma, biotech, devices)
Study start: 18 Nov 2022 (actual)
Primary completion: 9 Aug 2023 (actual)
Study completion: 9 Aug 2023 (actual)
First posted: 24 Oct 2022 (actual)
Results: Posted 1 Jul 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 4

Arm	Type	Receives
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution	Experimental	Drug: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Ketotifen fumarate ophthalmic solution 0.035%	Experimental	Drug: Ketotifen fumarate ophthalmic solution 0.035%Ketotifen fumarate ophthalmic solution 0.035%
Brimonidine tartrate ophthalmic solution 0.025%	Experimental	Drug: Brimonidine tartrate ophthalmic solution 0.025%Brimonidine tartrate ophthalmic solution 0.025%
Vehicle ophthalmic solution	Experimental	Drug: Experimental: Vehicle ophthalmic solutionVehicle ophthalmic solution

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (11 listed)

Subjects must:

Key exclusion criteria (10 listed)

Subjects may not:
Note: Subjects with fall induced asthma that is either mild persistent (defined as >1 per week, but <1 per day), moderate persistent, or severe persistent will be excluded.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution	Drug	Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Ketotifen fumarate ophthalmic solution 0.035%Ketotifen fumarate ophthalmic solution 0.035%	Drug	Ketotifen fumarate ophthalmic solution 0.035%
Brimonidine tartrate ophthalmic solution 0.025%Brimonidine tartrate ophthalmic solution 0.025%	Drug	Brimonidine tartrate ophthalmic solution 0.025%
Experimental: Vehicle ophthalmic solutionExperimental: Vehicle ophthalmic solution	Drug	Vehicle ophthalmic solution

Primary outcome

Ocular Itching Symptom Score
Time frame: Assessed up to 480 minutes post-instillation of assigned IP
Ocular itching score evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 is the worse outcome.
Ocular Redness Measured by Ocular Itching Scale
Time frame: Assessed up to 480 minutes post-instillation of assigned IP
Ocular redness evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.

3 secondary outcomes

Tearing Measured by Watery Eyes Scale
Time frame: up to 480 minutes post-instillation of assigned IP
Lid Swelling Measured by Eyelid Swelling Scale
Time frame: up to 480 minutes post-instillation of assigned IP
Chemosis Evaluated
Time frame: up to 480 minutes post-instillation of assigned IP

Results and safety

Results posted to the registry on 1 Jul 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution	58	57
Ketotifen Fumarate Ophthalmic Solution 0.035%	57	56
Brimonidine Tartrate Ophthalmic Solution 0.025%	58	56
Vehicle Ophthalmic Solution	56	56

Primary outcome: Ocular Itching Symptom Score

Time frame: Assessed up to 480 minutes post-instillation of assigned IP. Mean (Standard Deviation). Unit: score on a scale

Measure	Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution n = 57	Ketotifen Fumarate Ophthalmic Solution 0.035% n = 56	Brimonidine Tartrate Ophthalmic Solution 0.025% n = 58	Vehicle Ophthalmic Solution n = 56
Visit 2, Before Qualification ABC	0.175 (0.6031)	0.085 (0.3136)	0.267 (0.7549)	0.098 (0.3493)
Visit 2, 90 Minutes during Qualification ABC (Baseline)	2.728 (0.5830)	2.719 (0.5310)	2.659 (0.4581)	2.647 (0.5174)
Visit 2, 10 min Post-Instillation	1.807 (1.0501)	1.808 (0.8712)	1.991 (1.0163)	2.022 (0.8302)
Visit 2, 30 min Post-Instillation	1.443 (0.8914)	1.335 (0.8275)	1.513 (1.0621)	1.790 (0.8979)
Visit 2, 60 min Post-Instillation	1.110 (0.8737)	1.205 (0.9171)	1.220 (0.9425)	1.438 (0.7720)
Visit 2, 360 min Post-Instillation	0.811 (0.8599)	0.723 (0.7365)	1.125 (0.9485)	1.089 (1.0252)
Visit 2, 420 min Post-Instillation	0.851 (0.8568)	0.656 (0.7348)	1.078 (0.9461)	0.978 (0.8624)
Visit 2, 480 min Post-Instillation	0.961 (1.0020)	0.777 (0.8786)	1.009 (0.9188)	1.063 (0.9011)

Primary outcome: Ocular Redness Measured by Ocular Itching Scale

Time frame: Assessed up to 480 minutes post-instillation of assigned IP. Mean (Standard Deviation). Unit: score on a scale

Measure	Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution n = 55	Ketotifen Fumarate Ophthalmic Solution 0.035% n = 55	Brimonidine Tartrate Ophthalmic Solution 0.025% n = 58	Vehicle Ophthalmic Solution n = 56
Visit 2, Before Qualification ABC	1.218 (0.5815)	1.327 (0.5771)	1.384 (0.5815)	1.268 (0.6464)
Visit 2, 90 Minutes during Qualification ABC (Baseline)	2.469 (0.5430)	2.500 (0.5045)	2.642 (0.5832)	2.478 (0.4984)
Visit 2, 10 min Post-Instillation	1.127 (0.8253)	2.116 (0.6178)	1.293 (0.8194)	2.268 (0.6195)
Visit 2, 30 min Post-Instillation	0.934 (0.7388)	1.911 (0.6421)	1.103 (0.7609)	2.165 (0.7011)
Visit 2, 60 min Post-Instillation	0.904 (0.6924)	1.795 (0.7184)	1.026 (0.7517)	2.098 (0.6787)
Visit 2, 360 min Post-Instillation	1.316 (0.8245)	1.723 (0.7608)	1.405 (0.6896)	1.955 (0.6416)
Visit 2, 420 min Post-Instillation	1.456 (0.7936)	1.759 (0.7847)	1.582 (0.6873)	1.933 (0.6440)
Visit 2, 480 min Post-Instillation	1.553 (0.8125)	1.929 (0.8471)	1.832 (0.7757)	2.063 (0.7043)

3 secondary outcomes are reported in the full results.

Adverse events

Time frame: Assessed for approximately 8 hours after treatment. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution	0 of 57 (0%)	1 of 57 (1.8%)	0 of 57
Ketotifen Fumarate Ophthalmic Solution 0.035%	0 of 56 (0%)	6 of 56 (10.7%)	0 of 56
Brimonidine Tartrate Ophthalmic Solution 0.025%	0 of 58 (0%)	2 of 58 (3.4%)	0 of 58
Vehicle Ophthalmic Solution	0 of 56 (0%)	5 of 56 (8.9%)	0 of 56

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Individual participant dataSharing planned: No

Related trials for Seasonal Allergic Conjunctivitis

RecruitingObservational study
Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure
Allergic Rhinoconjunctivitis
Active, not recruitingObservational study
Tyrosine Allergoid Paediatric and Adult Study
Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis
RecruitingPhase 2
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
Allergic Conjunctivitis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

6 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Jul 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ocular Itching Symptom Score (time frame: Assessed up to 480 minutes post-instillation of assigned IP). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05591755.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2025.

Trial summary

Key requirements

Who may be able to join

Who cannot join

Trial locations and contacts

About this study

What participants receive

What is being measured

Timeline

Resources

More details

Study at a glance

Clinical summary

Study design

Who may qualify

Key inclusion criteria (11 listed)

Key exclusion criteria (10 listed)

Interventions

Primary outcome

Results and safety

Participant flow

Primary outcome: Ocular Itching Symptom Score

Primary outcome: Ocular Redness Measured by Ocular Itching Scale

Adverse events

Research links

Related trials for Seasonal Allergic Conjunctivitis

Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure

Tyrosine Allergoid Paediatric and Adult Study

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

Referral and contact

Questions about this trial

Participant flow

Primary outcome: Ocular Itching Symptom Score

Primary outcome: Ocular Redness Measured by Ocular Itching Scale

Adverse events